Skip Navigation

European Journal of Heart Failure 1999 1(3):275-279; doi:10.1016/S1388-9842(99)00037-9
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Auricchio, A.
Right arrow Articles by Spinelli, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Auricchio, A.
Right arrow Articles by Spinelli, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1999 European Society of Cardiology

Pacing for heart failure: selection of patients, techniques and benefits

Angelo Auricchioa,*, Helmut Kleina and Julio Spinellib

a Department of Cardiology, University Hospital Magdeburg, Germany
b Department of Research and Development, GUIDANT St Paul, MN, USA

* Corresponding author. Department of Cardiology, University Hospital, Leipziger str. 44, 39120 Magdeburg, Germany. Tel.: +49-391-67-15207; fax: +49-391-67-15211. E-mail address: angelo.auricchio{at}medizin.uni-magdeburg.de (A. Auricchio)

Key Words: Heart failure • Pacing • Multicenter trial • Conduction disturbances

Received April 7, 1999; Revised July 7, 1999; Accepted July 7, 1999


   1. Introduction
Top
 1. Introduction
2. Patient selection
 3. Technique for acute...
 4. Acute hemodynamic effect...
 5. End-points of the...
 References
 
Chronic heart failure is a syndrome characterized by left ventricular dysfunction, reduced exercise tolerance, impaired quality of life, and a markedly shortened life-expectancy [1,2]. A substantial proportion of patients with heart failure have electrical conduction disturbances. Recent data have shown that patients with chronic heart failure and conduction defects have a higher risk for cardiovascular events and a worse outcome [3,4]. Current pharmacological therapy administered to heart failure patients is, however, unable to directly correct the electrical conduction abnormalities present in these patients [2,5–8].

Many patho-physiological mechanisms could be advocated for the reported increase in adverse events observed for patients with chronic heart failure and electrical conduction defects. The prolongation of the PR interval in normal hearts is associated with a primary loss of the atrial contribution to ventricular mechanics [9,10]. However, in dilated cardiomyopathy patients, this prolongation can also have significant effects on diastolic filling [11], facilitating diastolic regurgitation [11]. The deleterious hemodynamic consequences of a prolonged PR interval are more evident for patients with severely depressed ventricular function. In these patients we can observe severe hemodynamic deterioration due to a prolonged mechanical atrio-ventricular interval, even in the presence of a normal PR due to the presence of large electromechanical delays [12]. Intra- and interventricular conduction delays, such as left bundle branch block prolong the pre-ejection time [13], reduce the global and regional ejection fraction, negatively affect the contraction and relaxation times, and prolong the duration of a pre-existing mitral regurgitation. The mechanical consequences of abnormal activation can be easily assessed by echocardiography; the M-mode echocardiography shows that in the right-bundle branch block, the onset of right-sided atrioventricular ring motion is delayed, and that the left is delayed in the left bundle branch block [14]. In addition, prolongation of ventricular depolarization, in particular the left bundle branch block generates discoordinate contraction, altering regional workload and stress [15]. The region of early activation contracts against minimal load, but wastes its energy, as no effective pressure develops since much of the rest of the cavity is still non-activated. The late depolarized region contracts against an already stiffened portion of the wall (i.e. the early-activated part) increasing its stress. If there is dyskinesis of the earlier depolarized region by the late activated region, then additional cardiac work is wasted-internally transferring ejection from one portion of the chamber to another. Changes in regional load might contribute to myocyte damage, including cell necrosis or apoptosis and replacement fibrosis.

The results of small, uncontrolled studies [16,17] suggested that the restoration of properly timed atrial and ventricular contractions by implantation of a conventional right-ventricular dual-chamber pacemaker was beneficial in the treatment of patients with chronic heart failure. These studies were conducted on patients who failed to respond to aggressive pharmacological therapy. These preliminary results, however, were not reproduced when better-controlled studies were conducted [18,19]. On the other hand, more consistent and positive data have been presented when the left ventricle has been paced alone [20] or simultaneously paced with the right one (biventricular stimulation) [21–24]. Some of the reasons that might be responsible for this discrepant findings are: patient selection; lack of clearly defined inclusion and exclusion criteria; statistical design; technique used for guiding the selection of the atrioventricular delay pacing site; and the study end-points [25].


   2. Patient selection
Top
 1. Introduction
 2. Patient selection
3. Technique for acute...
 4. Acute hemodynamic effect...
 5. End-points of the...
 References
 
The recognition that conduction disturbances might be responsible for a degraded coordination of the atrio-ventricular, and intra-ventricular contractions — and that this lack of coordination might play a key role for worsening left ventricular function — led to the development of a prospective randomized trial to test the effect of applying pacing therapy to patients with moderate to severe chronic heart failure. The PAcing THerapies in Chronic Heart Failure (PATH-CHF) study includes patients who had symptoms of moderate to severe heart failure. All the patients included in the trial had a New York Heart Association Functional Classification of III (for at least 6 months) or IV despite treatment at the maximum tolerated dosage with diuretics, an angiotensin-converting enzyme inhibitor, digitalis, vasodilators or nitrates and β-blockers. All the patients had dilated cardiomyopathy of any etiology, heart rate higher than 55 bpm, QRS complex duration wider than 120 ms in at least two surface-ECG leads (maximum of leads II, V1, V6) and a PQ interval longer than 150 ms. Patients with conventional indications for pacemaker implantation were excluded from the study. A complete list of exclusion criteria has been previously published [26].

The PATH-CHF Study consisted of an acute testing phase using the FLEXSTIMTM system during the implantation procedure, and of a randomized crossover protocol which tests two different pacing modes (univentricular or biventricular pacing) with a no-pacing (wash-out) period in-between.

The randomization procedure included two arms. In the first arm we applied atrial triggered univentricular pacing for 4 weeks (right or left ventricle). The other received atrial triggered biventricular pacing for 4 weeks (simultaneous right and left ventricle). At the end of the 4-week pacing period, the pacemakers were programmed off in all patients for the next 4 weeks. After these 4 weeks of no-pacing therapy, the patients were crossed over to the other pacing mode, and pacing therapy was restarted again for another 4 weeks. The study protocol was completed after 12 weeks. All the included patients are going to be followed up for 1 year.


   3. Technique for acute testing
Top
 1. Introduction
 2. Patient selection
 3. Technique for acute...
4. Acute hemodynamic effect...
 5. End-points of the...
 References
 
The rationale for the FLEXSTIMTM acute protocol was to measure the cardiac response to pacing [27]. In fact, a controlled study of pacing chamber and AV delay is technically difficult because of the large number of treatment combinations. The analysis of the acute hemodynamic effects of pacing using the standard methodology (e.g. cardiac output determined by thermo-dilution or by Doppler examination [28]) is time consuming and may not provide sufficient data for meaningful statistical comparisons of the different pacing sites and AV delays in a single patient. This is due to the fact that these techniques can have measurement errors that are in the same order of magnitude than the changes that we are trying to detect [29]. Therefore, they force the use of group statistics to try to get around this technical limitation. Nevertheless, group statistics will also be misleading when there are large interactions between individuals and pacing variables, preventing the elimination of the measurement errors present in the above mentioned techniques by the use of population averages [30]. In addition, normal physiological oscillations in the baseline during the study period will also affect the measurements and need to be corrected [31]. The unknown periodicity of these baseline changes, makes this source of error very difficult to eliminate.

The ‘FLEXSTIMTM protocol’ was specifically designed to address the issues mentioned above. It consists of periods of pacing in VDD mode (i.e. atrial sense followed by a ventricular pace after an atrio-ventricular delay) separated by periods of no pacing in normal sinus rhythm in a 5-paced beat/15-non-paced beat duty cycle. When pacing and no pacing sequences were interrupted by a premature ventricular contraction (PVC) additional beats were added to allow the PVC beat and surrounding beats to be removed from the analysis.

Pacing has been performed in the right ventricle (RV), left ventricle (LV), or right and left ventricles (biventricular) simultaneously (BV) at one of five different AV delays. The five AV delays were equally distributed between 0 ms and 30 ms less than the patient’s intrinsic PR interval as measured by the intracardiac electrograms. Each treatment combination of pacing chamber and AV delay has been repeated five times in random order for each patient. The entire sequence summed to 1500 beats, which, at an average heart rate of 75 bpm, required 20 min.


   4. Acute hemodynamic effect of pacing
Top
 1. Introduction
 2. Patient selection
 3. Technique for acute...
 4. Acute hemodynamic effect...
5. End-points of the...
 References
 
The major finding of the acute testing during the PATH-CHF study was that the acute left ventricular systolic function of most patients with moderate to severe CHF and left ventricular systolic dysfunction was significantly improved acutely by paced ventricular pre-excitation at an optimal combination of AV delay and site (Fig. 1). Left ventricular diastolic and right ventricular systolic function changed minimally [27]. In this patient population, which is dominated by left ventricular conduction disorders, left ventricular stimulation alone or in combination with right ventricular stimulation substantially increases the hemodynamic benefits when compared to right ventricular stimulation alone. In addition, two patients groups have been retrospectively identified, that have opposite acute pacing responses [27]. Curiously, these two groups are characterized by different surface QRS widths: patients with sufficiently wide QRS (>150 msec) exhibit large positive hemodynamic changes with pacing (Type I), while patients with narrower QRS (<150 msec) exhibit predominantly negative hemodynamic changes with pacing (Type II). However, even for the 20% who exhibited negative pacing effects, hemodynamic function could be optimized by individualized selection of AV delay and pacing chamber [27].


Figure 1
View larger version (34K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1 Distribution of the Pulse Pressure and LV+dP/dt in the 42 patients acutely tested in the PATH-CHF study. The patients have been consecutively presented according to the implantation number. A large variability among the patients in the three different pacing modes was evident. Also a large interindividual variability is evident. Changes in pulse pressure and LV+dP/dt are often algebraically correlated but not in their magnitude.

 
The discrepancy between the acute data of the PATH-CHF study on individuals (Fig. 1) and the recently published population results from Shinbane et al. [32] and Gold et al. [18] on RV pacing is not surprising, considering the effects of RV pacing are weak and strongly patient dependent. Roughly half the Type I patients exhibit <5% increases in LV+dP/dt and pulse pressure with RV pacing and while the other half increases >5%, only a few patients increase LV+dP/dt >20% with RV pacing. If these acute differences are predictive of chronic pacing benefit, the seemingly contradictory results of Hochleitner et al. [16], Auricchio et al. [9], Gold et al. [18] and Linde et al. [19] on the benefit of RV pacing might be explained by fortuitous differences in clinical patient populations. On the other hand, the consistently reported positive chronic results that have been obtained when pacing the left ventricle may be related to the large positive hemodynamic response to left sided pacing that we have observed in a majority of the PATH-CHF patient population.

Given that CHF patients have heterogeneous symptoms, etiologies, and substrates, and also that pacing may operate through multiple mechanisms (that in turn may require individual optimization), we should not be surprised by the conflicting chronic results that have been reported up to now. The data of the PATH-CHF study show that pacing can produce both positive and negative hemodynamic effects, at least acutely. The outcome seems to depend on the pacing site and AV delay, but most significantly on the individual patient. The most important individual variable for predicting acute pacing benefit in this study seems to be the QRS width. If the distinction between Type I and Type II patients also applies to chronic pacing benefit, studies including a mixture of such patients may produce mixed results. Thus, it would seem important to account for these individual variations in future studies of pacing therapy for CHF. By selecting the optimal pacing parameters for each individual patient, the negative effects of pacing Type II patients can be minimized. And the positive effects of pacing on the Type I patients can be maximized, with optimized cardiac output increase being two to four times larger than with sub-optimal pacing.


   5. End-points of the study
Top
 1. Introduction
 2. Patient selection
 3. Technique for acute...
 4. Acute hemodynamic effect...
 5. End-points of the...
References
 
The primary end-points of the PATH-CHF trial were to compare the relative benefit of pacing vs. no pacing using objective measures of: maximum oxygen consumption, oxygen consumption at anaerobic threshold, and changes in a 6-min walk distance. In addition, changes in functional class as assessed by the NYHA classification, in the quality-of-life measured according to the Minnesota Living with Congestive Heart Failure questionnaire, and the modifications in left ventricular ejection fraction were recorded. Another objective of this study was to compare the effects of uni-ventricular and BV pacing on the already listed parameters.

The PATH-CHF study is still an ongoing trial; a total of seven active centers enrolled 42 patients to date. The study is expected to be completed by the end of 1998 and the first quarter of 1999. Preliminary data of the PATH-CHF study indicates that the benefit achieved during the pacing period are of similar extension to what have been recently reported by Gras et al. [33]. Preliminary data of the PATH-CHF study indicates that significant benefit occurs during the pacing periods, these results have been reported elsewhere [26]. The magnitude of the observed changes are similar to the ones reported by the uncontrolled InSync trial [33]. This latter study showed that 12 weeks of continuous biventricular pacing was effective in prolonging the walked distance as well as in improving the functional class and the feeling-of-well being in the vast majority of the patients.

In conclusion, theoretical data, acute results and clinical observations now join force to suggest that amelioration of signs and symptoms of chronic heart failure may occur in selected patients with moderate to severe chronic heart failure after implantation of an appropriately programmed pacemaker. Furthermore, early data indicate that the addition of sequential pacing therapy to conventional optimal medical therapy might be associated with prolongation of exercise capacity, a reduction of norepinephrine plasma level, [34] improvement of functional class and feeling of well being among patients with moderate to severe chronic heart failure and electrocardiographic documented conduction defects. The final results from three prospective randomized ongoing studies, the PATH-CHF, VIGOR CHF and VENTAK CHF trials will help in the understanding of this potential new therapeutic alternative. But, even if the preliminary positive effects of pacing are validated, there is no doubt that a survival trial will be still needed to unequivocally demonstrate the long-term efficacy of this non-pharmacological approach. If the results of the PATH-CHF trial are positive, at this point in time, it should be considered that pacing therapy only applies to those patients who fulfill the described inclusion criteria of the prospective randomized trials, and further experiences are needed for other patient population. Our acute data also seems to support that, unless an acute optimization is performed before implant, a minimum QRS width of 150 ms should be required [35].


   References
Top
 1. Introduction
 2. Patient selection
 3. Technique for acute...
 4. Acute hemodynamic effect...
 5. End-points of the...
 References
 

  1. Cohn J.N., Johnson G., Ziesche S., Cobb F., et al. A Comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 325:303–310.[Abstract]
  2. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol (1983) 2:755–763.[Abstract]
  3. Stevenson W.G., Stevenson L.W., Middlekauff H.R., et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol (1996) 28:1458–1463.[Abstract]
  4. Aaronson K.D., Schwartz S., Chen T.-M., Wong K.-L., Goin J.E., Mancini D.M. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation (1997) 95:2660–2667.[Abstract/Free Full Text]
  5. Packer M., Gheorghiade M., Young J., et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med (1993) 329:1–7.[Abstract/Free Full Text]
  6. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet (1993) 342:821828.
  7. Goldman S, Johnson G, Cohn J.N, Cintron G, Smith R, Francis G. for the V-He FT VA Cooperative Studies Group. Mechanism of death in heart failure. The vasodilator-heart failure trials. Circulation (1993) 87:VI-24–VI-31.
  8. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med (1996) 334:1349–1355.[Abstract/Free Full Text]
  9. Auricchio A., Stellbrink C., Block M., Mortensen P. Clinical and objective improvements in severe congestive heart failure patients using univentricular or biventricular pacing: preliminary results of a randomized prospective study (Abstract). J Am Coll Cardiol (1998) 31:31A.
  10. Auricchio A., Ding J., Kramer A., Salo R., Hoersch W., Spinelli J. Are preload and optimum pacing mode associated in CHF patients (Abstract). Pacing Clin Electrophysiol (1998) 21:957.
  11. Brecker S.J.D., Xiao H.B., Sparrow J., Gibson D.G. Effects of dual-chamber pacing with short atrioventricular delay in dilated cardiomyopathy. Lancet (1992) 340:1308–1312.[CrossRef][Web of Science][Medline]
  12. Auricchio A., Salo R.W. Acute hemodynamic improvements by pacing in patients with severe congestive heart failure. Pacing Clin Electrophysiol (1997) 20:313–324.[CrossRef][Medline]
  13. Xiao H.B., Brecker S.J.D., Gibson D.G. Differing effects of right ventricular pacing and left bundle branch block on left ventricular function. Br Heart J (1993) 69:166–173.[Abstract/Free Full Text]
  14. Brecker S.J.D., Gibson D.G. What is the role of pacing in dilated cardiomyopathy? Eur Heart J (1996) 17:819–824.[Free Full Text]
  15. Curry C.W., Fetics B., Wyman B., Mc Veigh E., Kass D.A. Mechanical dysynchrony at rest and with adrenergic stimulation in patients with dilated cardiomyopathy studied by MRI-Tagging: Can it help identify candidates for chronic VDD pacing therapy? (Abstract). Circulation (1998) 17:I–302.
  16. Hochleitner M., Hörtnagl H., Ng C.K., Gschnitzer F., Zechmann W. Usefulness of physiologic dual-chamber pacing in drug resistant idiopathic dilated cardioyopathy. Am J Cardiol (1990) 66:198–202.[CrossRef][Web of Science][Medline]
  17. Auricchio A., Sommariva L., Salo R.W., Scafuri A., Chiariello L. Improvement of cardiac function in patients with severe congestive heart failure and coronary disease by dual chamber pacing with shortened AV delay. Pacing Clin Electrophysiol (1993) 16:2034–2043.[CrossRef][Medline]
  18. Gold M.R., Feliciano Z., Gottlieb S.S., Fisher M.L. Dual-chamber pacing with short atrioventricular delay in congestive heart failure: a randomized study. J Am Coll Cardiol (1995) 26:967–973.[Abstract]
  19. Linde C., Gadler F., Edner M., Nordlander R., Rosenqvist M., Ryden L. Results of atrioventricular synchronous pacing with optimized delay in patients with severe congestive heart failure. Am J Cardiol (1995) 75:919–923.[CrossRef][Web of Science][Medline]
  20. Blanc J.J., Etienne Y., Gilard M., et al. Evaluation of different ventricular pacing sites in patients with severe heart failure. Results of an acute hemodynamic study. Circulation (1997) 96:3273–3277.[Abstract/Free Full Text]
  21. Bakker P.F., Meijburg H., de Jonge N., et al. Beneficial effects of biventricular pacing in congestive heart failure (Abstract). Pacing Clin Electrophysiol (1994) 17:820.
  22. Cazeau S., Ritter P., Lazarus A., et al. Multisite pacing for end-stage heart failure: early experience. Pacing Clin Electrophysiol (1996) 19:1748–1757.[CrossRef][Medline]
  23. Kass D.A., Chen C.H., Fetics B., Talbot M., Nevo E., Nakayama M. Ventricular function in patients with dilated cardiomyopathy is improved by VDD pacing at left but not right ventricular sites (Abstract). J Am Coll Cardiol (1998) 31:1015–1029.
  24. Saxon L.A., Kerwin W.F., Cahalan M.K., et al. Acute effects of intraoperative multisite ventricular pacing on left ventricular function and activation/contraction sequence in patients with depressed ventricular function. J Cardiovasc Electrophysiol (1998) 9:13–21.[Web of Science][Medline]
  25. Auricchio A., Klein H. Dual-chamber pacing in dilated Cardiomyopathy: insufficient sample size, heterogeneous population and inappropriate end points may lead to erroneous conclusions. Letter to the editor. J Am Coll Cardiol (1996) 27:1548.[Web of Science][Medline]
  26. Auricchio A., Stellbrink C., Sack S., et al. The Pacing Therapies for Congestive Heart Failure (PATH-CHF) Study: rationale, design and end-points of a prospective randomized multicenter study. Am J Cardiol (1999) 83(Suppl_5B):130D–135D.[CrossRef][Web of Science][Medline]
  27. Auricchio A., Stellbrink C., Block M., et al. The effect of pacing chamber and atrio-ventricular delay on acute systolic function of paced patients with congestive heart failure. Circulation (1999) 99:2993–3001.[Abstract/Free Full Text]
  28. Leitch J., Dear K., Chevalier S., Basta M., Hardy D. Feasibility of measuring the ‘optimal atrioventricular delay’ (Abstract). J Am Coll Cardiol (1997) 29:432A.
  29. Enghoff E., Michaelsson M., Pavek K., Sjogren S. A comparison between the thermal dilution method and the direct Fick and the dye dilution methods for cardiac output measurements in man. Uppsala J Med Sci (1978) 75:157.
  30. Nishimura R.A., Hayes D.L., Holmes D.R., Tajik A.J. Mechanism of hemodynamic improvement by dual-chamber pacing for severe left ventricular dysfunction: an acute Doppler and catheterization hemodynamic study. J Am Coll Cardiol (1995) 25:281–288.[Abstract]
  31. Packer M., Medina N., Yushak M. Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. Circulation (1985) 71:761–766.[Abstract/Free Full Text]
  32. Shinbane J.S., Chu E., DeMarco T., et al. Evaluation of acute dual chamber pacing with a range of atrioventricular delays on cardiac performance in refractory heart failure. J Am Coll Cardiol (1997) 30:1295–1300.[Abstract]
  33. Gras D., Mabo P., Tang T., et al. Multisite pacing as a supplemental treatment of congestive heart failure: preliminary results of the Medtronic Inc, InSync Study. Pacing Clin Electrophysiol (1998) 21:2249–2255.[CrossRef][Medline]
  34. Saxon L.A., De Marco T., Chatterjee K., et al. The magnitude of sympathoneural activation in advanced heart failure is altered with chronic biventricular pacing (Abstract). Pacing Clin Electrophysiol (1998) 21:914.
  35. Auricchio A., Klein H., Tockman B., Sack S., Stellbrink C., Neuzner J., Kramer A., Ding J., Pochet T., Maarse A., Spinelli J. Transvenous biventricular pacing for heart failure: can the obstacles be overcome. Am J Cardiol (1999) 83 [Suppl 5B]:136D–142D.

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
A.P. Coletta, N. Nikitin, A.L. Clark, and J.G.F. Cleland
Clinical trials update from the American Heart Association meeting: PROSPER, DIAL, home care monitoring trials, immune modulation therapy, COMPANION and anaemia in heart failure
Eur J Heart Fail, January 1, 2003; 5(1): 95 - 99.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
J.G.F. Cleland, J.C. Daubert, E. Erdmann, N. Freemantle, D. Gras, L. Kappenberger, W. Klein, L. Tavazzi, and The CARE-HF study Steering Committee and Investiga
The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points
Eur J Heart Fail, August 1, 2001; 3(4): 481 - 489.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Auricchio, A.
Right arrow Articles by Spinelli, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Auricchio, A.
Right arrow Articles by Spinelli, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?